Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells

Noriko Kimura, Yoshitaka Miyakawa, Kanoko Kohmura, Kazuo Umezawa, Yasuo Ikeda, Masahiro Kizaki

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A new NF-κB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction of apoptosis by DHMEQ was prevented by the pretreatment of Burkitt lymphoma cells with pan-caspase inhibitor, z-VAD-FMK. The expression of anti-apoptotic factors such as IAP-1 and XIAP was suppressed by DHMEQ. Phosphorylation of ERK and JNK was induced by DHMEQ. In conclusion, these results demonstrate that NF-κB might be an ideal target to develop for new anti-cancer drugs for Burkitt lymphoma.

Original languageEnglish
Pages (from-to)1529-1535
Number of pages7
JournalLeukemia Research
Volume31
Issue number11
DOIs
Publication statusPublished - 2007 Nov 1

Keywords

  • Apoptosis
  • Burkitt lymphoma
  • Caspase-3
  • IAP
  • NF-κB

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells'. Together they form a unique fingerprint.

  • Cite this